Related Experiment Video
Updated: Jul 17, 2026
11:44
Synthesis and Structure Determination of µ-Conotoxin PIIIA Isomers with Different Disulfide Connectivities
Published on: October 2, 2018
Interactions between alpha-conotoxin MI and the Torpedo marmorata receptor alpha-delta interface
Leonardo Cortez1, Cristina Marino-Buslje, Mirtha Biscoglio de Jiménez Bonino
1Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Instituto de Química y Fisicoquímica Biológicas (UBA, CONICET), Junín 956 (1113), Buenos Aires, Argentina.
Biochemical and Biophysical Research Communications
|February 13, 2007
Summary
Alpha-conotoxin MI selectively binds to nicotinic acetylcholine receptors. This study identified specific binding sites on the Torpedo marmorata receptor, revealing a second binding motif at the alpha/delta interface.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Muscle-type nicotinic receptors possess distinct acetylcholine binding sites at alpha-gamma and alpha-delta subunit interfaces.
- Alpha-conotoxins exhibit selective binding to these sites.
- Previous work demonstrated alpha-conotoxin MI interaction with nicotinic receptors from different Torpedo species.
Purpose of the Study:
- To identify the specific regions of the Torpedo marmorata nicotinic acetylcholine receptor involved in alpha-conotoxin MI binding.
- To elucidate the interaction mechanism between alpha-conotoxin MI and its receptor.
Main Methods:
- Photoactivatable reagent labeling of the receptor.
- Enzymatic proteolysis for site mapping.
- Mass spectrometry (MALDI-TOF-MS) and Edman degradation for peptide analysis.
- In silico docking studies.
Main Results:
- Identified key binding determinants for alpha-conotoxin MI on the Torpedo marmorata receptor.
- Discovered a second binding motif for alpha-conotoxin MI at the alpha/delta subunit interface.
- Provided experimental evidence for the toxin-receptor interaction.
Conclusions:
- Alpha-conotoxin MI interacts with at least two distinct sites on the Torpedo marmorata nicotinic acetylcholine receptor.
- The alpha/delta interface represents a significant binding region.
- Experimental data and docking studies offer insights into the molecular basis of conotoxin-receptor interaction.
Related Concept Videos
01:09Multi-pass Transmembrane Proteins and β-barrels
In multi-pass transmembrane proteins, the polypeptide chain crosses the membrane more than once. The transmembrane polypeptide chain either forms an α-helix or β-strand structure. α-Helix containing multi-pass transmembrane proteins are ubiquitous, whereas β-strand containing ones are mainly found in gram-negative bacteria, mitochondria, and chloroplasts.
α-Helix containing multi-pass transmembrane proteins
Multi-pass transmembrane proteins such as G-protein-linked receptors (GPCRs) and...
α-Helix containing multi-pass transmembrane proteins
Multi-pass transmembrane proteins such as G-protein-linked receptors (GPCRs) and...
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
01:29Drug-Receptor Interactions
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
01:29Neuromuscular Junction And Blockade
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...